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HIV has a Woman's Face
According to Nelson Mandela, who spoke about
the disproportionate burden of HIV infection on
women at a recent event in South Africa, the
world wide epidemic of HIV is taking on the face
of a woman.1 Due to their status in society and
for physiological reasons discussed in greater
detail below, women are disproportionately at risk
for HIV infection, and this is particularly true for
women who are incarcerated. 
The overall prevalence of HIV infection among
U.S. women is approximately 0.2%; incarcerated
women are 15 times more likely to be HIV-infect-
ed compared to women in the general population.
In several states, nearly one in 10 incarcerated
women are HIV-infected. At yearend 2002, 3% of
all incarcerated women in U.S. state prisons were
HIV-infected, compared to 2% of incarcerated
men in U.S. state prisons (Table 1.)  More than
10% of female inmates in two states (New York
and Maryland) were known to be HIV-infected.2
Social Factors 
Incarcerated women have higher prevalence
rates of HIV infection than incarcerated men
because the behaviors for which they are incar-
cerated put them at risk for HIV infection.3,4 They
are often injection drug users (IDUs), sexual part-
ners of IDUs, have supported themselves
through sex work, and more often than not, they
have been forced to have (unprotected) sex or
trade sex for housing and food.5 Women who are
more likely to be HIV-infected in the U.S. also
belong to subgroups of the population that are at
increased risk of incarceration: women living in
poverty, women who lack marketable job skills,6
and certain ethnic groups (African American,
Hispanic). Many of the women at highest risk for
HIV infection are unaware of their risk, have little
or no access to HIV prevention, and are afraid,
for fear of violence, to ask their partners to use
condoms.7
These risk factors are clearly demonstrated in
one of the most recent published studies of incar-
cerated women. Researchers in Brazil inter-
viewed and evaluated 290 incarcerated females
and found prevalence rates for HIV, hepatitis C
virus (HCV), and syphilis of 13.9%, 16.2%, and
22.8%, respectively. The most significant risks for
HIV infection included HIV-infected sexual part-
ners, casual partners, partners who inject drugs,
and a history of sexually transmitted infections
(STIs). Even women with a single sex partner
presented a significant risk for HIV infection,
reflecting their vulnerability for acquiring HIV
infection, most likely due to their trust in their part-
ner who did not use a condom. While the use of
injectable drugs was associated with HIV infec-
tion, the study results pointed to sexual behavior
as the most important component of HIV trans-
mission in the incarcerated female population.8 
Mental Health Factors
Mental illness is a common co-morbidity for HIV-
infected incarcerated women. A number of stud-
ies have linked prior childhood experiences of
abuse and neglect with women's healthcare
needs, mental health needs, and HIV risk behav-
iors. According to self-reported data, 33%-65% of
incarcerated women in the US report prior sexual
abuse and 19%-42% report a history of childhood
sexual abuse.9,10 These percentages are likely
under-representative of the prevalence of abuse
histories among incarcerated women, but they
are still two-fold higher than the prevalence of
such histories among women who are not incar-
cerated. 
Mental health problems contribute to the high
prevalence of HIV infection among incarcerated
women and make the management of their HIV
care substantially more challenging. In a recent
US study, 25% of women discontinued highly
active antiretroviral therapy (HAART) for at least
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six months during study follow-up of five years, and women who dis-
continued HAART were more likely to be depressed than those who
did not discontinue medication.11 Access to treatment for depression
may be helpful for improving the management of HIV-infected incar-
cerated women.
Since many incarcerated women have experienced childhood sexual
abuse and adult sexual trauma, gynecological and obstetric exami-
nation takes special care and sensitivity. Some of the issues that may
interfere with the examination of sexually abused women include their
need to trust the examiner, their need for control (wishing to control
the time and place of the exam), their fear of disclosure, and their fear
of having their body touched during the exam.12 Sensitive gynecolog-
ical healthcare providers are critically important members of the cor-
rectional HIV management team.
Biological Factors
HIV transmission estimates vary by the type of exposure. Per-event
transmission probability estimates are 0.7%  (about one in 150) per
episode of intravenous needle or syringe sharing, and 0.09% (less
than one in 1,000) after a mucous membrane exposure (such as a
splash to eyes or mouth). The risk for HIV transmission per episode
of receptive penile-anal sexual intercourse is estimated at 0.1%-
3.0%, while the risk per episode of receptive vaginal intercourse is
estimated at 0.1%-0.2%. While published estimates of the risk for HIV
transmission from receptive oral exposure do not exist, instances of
suspected transmission have been reported.13,14
Data has suggested that men with HIV infection are biologically more
likely to transmit HIV than women, due to increased genital shedding
of HIV-1, leading to the thought that male-to-female transmission is
more efficient than female-to-male transmission during asymptomatic
infection (early in HIV disease). However, the risk of transmission dur-
ing symptomatic infection does not appear to vary.15 In a recent study
in Uganda, plasma HIV RNA levels and genital ulcer disease, but not
gender, were the main determinants of HIV transmission16. There is
also recent data that shows higher levels of HIV in semen versus
female genital tract secretions. Collectively, these data may suggest
that women are at a greater risk for infection as compared to men.  
Additionally, incarcerated women, in general, and HIV-infected incar-
cerated women in particular, have remarkably high rates of STIs and
gynecologic infections, which are associated with higher risks of HIV
infection.15 At yearend 2003, 1.8%, 6.3%, and 7.5% of incarcerated
women tested positive for gonorrhea, chlamydia, and syphilis,
respectively.17 In younger women, cervical ectopy (extra mucosal tis-
sue around the entry to the cervical canal) makes the cervix more vul-
nerable to HIV infection.18
High rates of STIs are associated with high risk for HIV infection for
three main reasons:
1. Unprotected sex that results in the transmission of an STI can also
result in HIV transmission. 
2. STIs can cause genital lesions and recruit white blood cells to the
region which may increase a person's susceptibility to HIV infection. 
3. Persons who are co-infected with HIV and an STI may have
increased HIV shedding in genital secretions, thereby increasing the
chances that the co-infected person will infect another person if he or
she engages in unprotected sex.
High rates of syphilis among incarcerated women have prompted a
number of studies assessing methods of syphilis screening and treat-
ment in the correctional setting. Several studies have shown the effi-
cacy of administering qualitative rapid plasma reagin (RPR) testing
for syphilis.19,20 A study conducted at a New York City jail found that
qualitative nontreponemal syphilis testing, online access to the local
syphilis registry, and immediate treatment (if indicated), following
admission, increased the rate of syphilis treatment from 7% to 84% of
cases.21
Testing for or making a diagnosis of an STI provides an important
opportunity for healthcare providers to counsel inmates about the
iss e of HIV transmission. HIV testing should be offered at each HIV
encounter.  Rapid HIV testing (Table 2) is a particularly important tool
for getting HIV-infected women into care; more than 98% of individu-
als are able to receive their test results and most enter care following
rapid test diagnosis.22
Incarcerated Women and Motherhood
Between 1998-1999, 1,400 women gave birth within prisons. During
this time, in Georgia alone, more than 150 women who entered prison
were pregnant.24 Both the number of HIV-infected women giving birth
in prisons and the extent of prenatal screening for HIV infection that
is performed in federal and state prisons are unknown at this time.
Even though mother-to-child transmission (MTCT) of HIV has been
all but eradicated in the U.S., MTCT still occurs among high-risk
women who seek care late in the course of pregnancy. Between 280-
370 U.S. babies continue to be born each year with HIV infection.25
Prior to the institution of MTCT prevention, transmission from HIV-
infected mother to child ranged from 16%-25% in North America and
Europe. Today, the risk of perinatal transmission can be less than 2%
with effective antiretroviral therapy (ART), elective cesarean section
as appropriate, and formula feeding. 
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Table 1: HIV Prevalence in U.S. Prisons
HIV by Gender in
2002
Jurisdiction
Federal
State
Connecticut
New York
Georgia
Florida
Texas
Nevada
Male HIV Cases*
Number Percent
1,431 1.1
19,297 1.9
563 3.3
4,590 7.2
1,023 2.3
2,508 3.6
2,261 1.8
98 1.01
Female HIV Cases
Number Percent
116 1.2
2,053 3.0
103 7.2
410 13.6
100 3.2
340 7.4
267 2.7
15 4.2
HIV Rapid Test
Ora-Quick Advance
HIV-1/2 Antibody
Uni-Gold Recombigen
HIV
Reveal Rapid HIV-1
Antibody
Multispot HIV-1/HIV-2
Murex SUDS HIV-1
Notes
w Store at room temp
w Screens for HIV-1 and -2
w Results in 20 mins
w Store at room temp
w Screens for HIV-1
w Results in 10 mins
w Reagents need reconstitution and  
refrigeration
w Screens for HIV-1
w Results in 5 mins
w Reagents need refrigeration
w Screens for HIV-1 and HIV-2
w Results in 15 mins
w Screens for HIV-1
*HIV testing is not mandatory in most states. Therefore, the prevalence
of HIV infection is likely to be significantly underreported. Data derived
in Table 1 from Maruschak, 2004. 
*95% Confidence Interval
Table 2: FDA-Approved HIV Rapid Testsxxiii
3The correctional setting clearly provides a critical opportunity to reach
women who may not have accessed pre-natal testing in the commu-
nity and routine pre-natal screening in correctional settings may be
cost-effective.26 According to standards set forth by Centers for
Disease Control and Prevention (CDC), thorough and non-judgmen-
tal discussion of HIV testing and ART is a required component of all
pre-natal care.27
Certain aspects of long-term incarceration, such as shelter, food, and
sobriety may be health promoting for high-risk pregnant women and
have been reported to improve their pregnancy outcomes.28However,
few correctional facilities allow women to house their infants in a nurs-
ery at the institution after delivery (residential programs for infants
exist in only 11 states and select federal facilities). Most correctional
facilities remove newborns from their mothers during or immediately
after the hospital stay. 
Most incarcerated women are mothers and were the custodial parent
of a minor child prior to incarceration. In 1998, 70% of women in jails,
65% of women in state prisons, and 59% of women in Federal pris-
ons had at least one child under the age of 18 at home. The total num-
ber of minor children whose mothers were in federal or state prisons
increased from 61,000 in 1991 to 110,000 in 1998. In 1998, 84% and
64% of minor children whose mothers were in federal and state pris-
ons, respectively, lived with their mothers before their mothers
entered prisons. Women are allowed to receive visits by their children.
However, these visits are infrequent; 56% of women do not see their
children at all while they are incarcerated.29 The impact of this sepa-
ration on the wellbeing of the mother and the bond between the moth-
er and infant deserves further study.
Incarcerated women at Risk for Hepatitis
The prevalence of HCV is much greater among incarcerated popula-
tions than the general public. The incidence of HCV in the US gener-
al population has been estimated at 1.8%, while the incidence among
state and federal facilities in 1999 was 2.1%. Incarcerated females
typically have high rates of HCV infection. In 1994, 63.5% of female
inmates entering the California correctional system were found to be
anti-HCV positive, compared to 39.4% of male inmates.30 Testing for
and appropriately treating HCV and hepatitis B virus (HBV) co-infec-
tion among incarcerated females should be a routine component of
HIV care.31 For more information on testing and treating HCV and
HBV, please refer to CDC's Sexually Transmitted Diseases Treatment
guidelines - 2002.32,33
Managing HIV infection
Because incarcerated women have a high prevalence of HIV infec-
tion, multiple sources of HIV risk in their lives, and limited access to
HIV testing and counseling services outside of prison or jail, there
should be multiple opportunities for women to say "yes" to HIV coun-
seling and education while they are incarcerated (Table 3.)  However,
the incarcerated woman's fear of stigmatization by her peers and cor-
rectional staff can have a negative impact on the detection and man-
agement of HIV/AIDS in prisons and jails. The closed setting of cor-
rectional institutions makes confidentiality difficult to maintain (partic-
ularly if a clinic or care provider is identified as being associated with
HIV), though total confidentiality should always be the goal. Peer
HIV/AIDS education programs may reduce stigmatization among pris-
oners and increase the general awareness of HIV in the incarcerated
female population.34
Factors that are likely to encourage incarcerated women to become
tested include concern about the impact of HIV infection on their pre-
sent or future children, and about having contracted HIV infection in
the context of having acquired other STIs.  Many incarcerated women
may have been tested for HIV during prior pregnancies and may
therefore be familiar with the concepts and procedures related to HIV
testing.  However, younger women (with fewer arrests, fewer preg-
nancies, and fewer opportunities to interact with HIV testers and
counselors) may be less familiar with the concept of HIV testing, and
hence, more fearful.
In many facilities the list of "risk factors" will include virtually every
fe ale prisoner in the institution. With HIV/AIDS prevalence rates
approximately 15 times higher among incarcerated women compared
to the general population, HIV testing should be regularly offered and
ea ily available to all women prisoners.
Considerations for Care
Ideally, correctional management of HIV would include a network of
interconnected services that would address the needs of HIV-infected
incarcerated women. These services might include clinical medical
services, physical and sexual abuse recovery programs, drug treat-
ment, and mental health services. They may also include vocational
training and skills building workshops that, by helping women to
become socio-economically more powerful, facilitate their ability to
continue to effectively manage their healthcare needs and to prevent
HIV transmission upon prison release. The opportunity to test and
tr at HIV-infected pregnant women who are incarcerated should not
be missed. Finally, discharge planning programs initiated during
incarceration can help connect women to community medical ser-
vices, drug treatment, support services that provide child care, safe
affordable housing, job training and employment opportunities that
will all serve to increase their ability to continue to care for their own
health needs.  Incarceration provides a critical opportunity for the edu-
cation, diagnosis, and medical care of HIV-infected women and high-
risk HIV seronegative women, as well as a critically important public
health opportunity to reduce the spread of HIV.
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HIV education and testing services should be offered on
multiple occasions to women who:
w Are pregnant or who are seeking pregnancy 
testing
w Have a current or prior STI diagnosis
w Have abnormal pap smear test results
w Have HBV or HCV
w Have a history of sex work
w Have a history of sexual abuse
w Have a history of drug use
w Have partners who use drugs
Table 3: HIV Education/Testing 
Continued on page 4
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prehensive, Internet-based library of practically applicable materials on
mother and child HIV infection including preventing mother-to-child HIV
transmission (PMTCT), infant feeding, clinical care of women and chil-
dren living with HIV infection, and the support of orphans. 
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ASK THE EXPERT: An HIV-infected inmate with an abnormal cervical Pap test
Bethany Weaver*, DO, MPH, Acting Instructor of Medicine, University of Washington Center for AIDS & STD Research (CFAR)
Disclosures: *Nothing to disclose.
CASE: A 30 year-old female inmate, G4P2, presents to the prison diagnostic intake clinic with a history of A2 HIV infection, last approximate
CD4 count 350 cells/µl and HIV-1 quantitative viral load (VL) 50,000 copies/ml, for which she is taking no medications and is antiretroviral ther-
apy (ART)-naive. She has a four-year sentence and a history of heroin dependence.  Her last Pap was performed approximately four years ago
when she was diagnosed with HIV, and she thinks it was normal. She reports being treated for chlamydia when diagnosed with HIV.  Her ex-
husband was HIV-infected and is now deceased. She reports no sex partners for at least 12 months. 
On physical exam, vital signs are normal, and she appears well nourished. She has no evidence of oral thrush or lymphadenopathy, her skin is
normal, and her chest, breast, and abdominal examinations are normal. Pelvic exam is notable for watery, grayish vaginal discharge with a fishy
odor, though on gross examination her cervix and vaginal wall appear normal.  Cells are collected from her cervix using a spatula and cytobrush
and a slide for conventional Pap test is prepared. A swab of the discharge from her vaginal wall is also collected. The vaginal pH is 6.0, and the
wet mount shows few lactobacilli. Laboratory tests to confirm her T cell count, HIV-1 viral load, electrolytes, and renal/hepatic function, and to
screen for hepatitis A,B,C, syphilis, chlamydia, gonorrhea, toxoplasmosis, and CMV are obtained. 
Q: What is the cause of her vaginal discharge and how should it be
treated?
A: She has bacterial vaginosis (BV), in which an overgrowth of bacte-
rial species (such as Gardnerella, Bacteroides, Mycoplasma,
Mobiluncus, and Peptostreptococcus) normally present in the vagina
occurs.  BV correlates with loss of protective (peroxide-producing) lac-
tobacilli normally present in the vagina, thereby raising the vaginal pH
above normal (>4.5). In non-pregnant women, BV is usually treated
with metronidazole at 500 mg po twice daily for seven days (250 mg
po three times daily for seven days in pregnancy).  Of note, in a recent-
ly published observational cohort study by Watts, et al., the authors
report that BV and Trichomonas vaginalis infection may increase the
risk of acquisition (or reactivation) of HPV infection among HIV-infect-
ed and high-risk HIV-uninfected women. 
She returns to clinic for follow-up of test results three weeks later.  Her
CD4 count is 334 cells/µl with HIV-1 VL of 85,000 copies/ml.  Her Pap
report states that it is "satisfactory for evaluation" and shows "atypical
squamous cells of undetermined significance (ASC-US)". Other tests
ord red are normal and show no evidence of hepatitis, syphilis, gon-
orrhea, or chlamydia.   
Q: How should her cervical cytology (ASC-US Pap) be managed?
Would ordering an HPV test be helpful?
A: This inmate should be referred for colposcopic examination since
she is HIV-infected and has an abnormal Pap, even if it is only mildly
abnormal. Also, even if the colposcopy is normal, she should have a
repeat Pap in six months since she has had only one Pap since her
diagnosis of HIV, and this was at least four years ago.  Women at high-
est risk of cervical cancer in the U.S. are those who are not properly
screened for cervical cancer. Because cervical cytology is only, on
average, 60% sensitive in detecting moderate to severe cervical
intraepithelial neoplasia (CIN grade 2/3) or cancer, other screening
Continued on page 5
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strategies, such as HPV DNA testing, are recommended for use in
some specific clinical scenarios relating to immunocompetent women.
However, studies, though limited, have shown that HPV DNA testing
in HIV-infected women may not be cost-effective or as clinically mean-
ingful compared to testing in immunocompetent women.  Therefore, in
the 2001 ASCCP guidelines for the management of women with cyto-
logical abnormalities, it was recommended that all HIV-infected
women (regardless of CD4 count or HIV-1 VL) with any cytological
abnormality, including ASC-US, be referred for colposcopy, in order to
ensure accurate and timely detection of CIN 2/3 or cancer.  Detection
of DNA for oncogenic HPV types among HIV-infected women with
ASC-US is more common than among HIV-uninfected women, and
therefore, does not appear to be a cost-effective strategy for deter-
mining who in this population should go to colposcopy. 
Q: Should this patient, who is largely asymptomatic from HIV infec-
tion, be treated with ART?
A: According to the recently revised 2004 DHHS ART guidelines,
treatment for this ART-naïve, asymptomatic inmate with a CD4 count
that is now <350 cells/µl should be offered.  If her CD4 count was >350
cells/µl, treatment could be deferred since her VL is <100,000
copies/ml.  It is unclear whether initiation of ART would aid in regres-
sion of cervical disease, by way of decreasing HIV-1 viral load and
increasing CD4 count. Prospective or randomized trials properly
designed to address this issue have not been published, and the data
that exists is conflicting. Of note, having cervical dysplasia does not
make a woman "symptomatic" from HIV disease, though this may
change in the future.  
DISCUSSION
Human papillomavirus (HPV), which is the most common sexually
transmitted infection, causes cervical dysplasia and squamous cell
cancer.  In 1999, Massad, et al. reported the prevalence of abnormal
cervical screening cytology among HIV-infected women to be approx-
imately 38%. Published reports on ASC-US cytology among HIV-
infected women suggest a 14-15% risk for CIN 2/3, and a more recent
study showed that HPV DNA testing in this population may not be sen-
sitive enough to use as a triage strategy for detecting CIN 2/3.  
Cervical cancer screening guidelines for HIV-infected women have not
been revised since 1995 and only state that these women should have
two Pap tests performed six months apart in the first year of the initial
HIV diagnosis.  If Pap results for both are normal, they can then go to
annual cytological screening.  A published report by Goldie, et al. sug-
gests that HPV DNA testing may be cost effective if performed in con-
junction with primary cervical cytological screening of women in the
first year of HIV diagnosis and then, if either is positive, used to triage
women who undergo more intensive screening thereafter (e.g. six
month intervals verses annually).  However, this published report was
a cost modeling study and has not been tested in a prospective or ran-
domized clinical trial.  In a recent observational cohort study by Harris,
et al., the authors showed there to be a similar cumulative incidence of
any cytological abnormalities, over three or more years, among HIV-
seronegative and HIV-seropositive women (CD4 counts greater than
500 cells/µl) who had normal cytology and negative HPV DNA tests at
baseline. These findings suggest that among HIV-infected women with
relatively preserved immune function (i.e. CD4 counts >500 cells/µl),
cervical cancer screening guidelines for immunocompetent women,
may apply.  However, these findings need to be confirmed in a prop-
erly designed formal clinical trial. Therefore, until more evidence is
available to suggest otherwise, HIV-infected women with ASC-US or
other cytological abnormalities should be referred for colposcopy.  
Just as little is known about the proper cervical cancer screening
strategies for HIV-infected women, the same is true for the manage-
ment of mild dysplasia, or CIN 1, in these women.  In immunocompe-
tent women, CIN1 is often observed and not treated, particularly in
younger women, since CIN 1 will often regress without treatment.  In
a published prospective cohort study by Massad et al., the authors
show that CIN 1 infrequently progresses to more severe disease,
including cancer, in women with HIV infection.  They concluded that
observation appears safe for these women (with the assumption that
they will be followed carefully and not lost to follow-up in the system).
In adult women, regardless of immune function, CIN 2/3 or worse dis-
ease should always be treated.
**Based largely on these data discussed above and the 2001
American Society for Colposcopy & Cervical Cytology (ASCCP)
Consensus Guidelines, Dr. Weaver provides in this issue a suggested
algorithm for HIV-infected women with cytological abnormalities.
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Dear Colleagues, 
According to UNAIDS, more than 40 million people are living with HIV today. Of these, 50% are
women. There is no question that the HIV epidemic is increasingly affecting women in the world.
This increased prevalence of HIV is seen in the U.S., especially among African-American and
Hispanic women. According to CDC and Prevention, in 2002, 28% of HIV cases diagnosed in the
U.S. were among women; 41% of HIV cases were among women aged 13-24 years. AIDS is
among the leading causes of death for young African-American women.
One of our longstanding traditions at IDCR is to honor women during the month of May by writing
about the impact of HIV on incarcerated women. Only one in seven inmates in the U.S. is female,
but the healthcare of these women is more complicated, and more costly, than the care of incar-
cerated men. This is because they have higher rates of STIs, HIV and HCV. These incarcerated
women are also burdened with higher rates of mental illness than male detainees due to intensive,
long-term exposures to sexual, physical and psychological violence.1 B cause these women have
more health problems, it is critically important to provide them healthcare. Reaching out to these
women while they are incarcerated, identifying and treating their HIV and HCV infections and
addressing their mental health needs, has an impact that reaches far beyond prison walls. 
More often than not, on the outside, these women are mothers, sisters, partners and caretakers.
Therefore, incarceration provides us an opportunity to inform women about HIV and HCV, to give
them the tools and treatment necessary to reduce their risk and better protect themselves from
infection if they are not already infected. If they are already infected, we can help them prevent
transmission of these infections to their partners and unborn children. 
The authors of the articles included in this issue of IDCR have been involved in the care of HIV-
infected women, inside and outside of prison, for the entire course of the HIV epidemic. They have
found that the care of these women can be as rewarding for the practitioner as it is for the patient.
Even though HIV or HCV infections have had a terrible impact on the lives of these women offend-
ers, those who have cared for them on the inside have witnessed their enormous resilience, a ill-
ingness to carry on and to improve their own health despite the many obstacles that they
encounter. One of the main factors that motivates them is the hope of regaining contact with and
custody of their children. It is our belief that caring for these women means that we are caring for
the communities - the families, the children, to whom they return, after release. 
Lastly, we would like to take this opportunity to thank our colleagues in the field for their dedication
to caring for HIV-infected women inside prison, and out. 
Respectfully,  
Beth Weaver, DO
1. Browne, A, et al.  Prevalence and severity of lifetime physical and sexual victimization among incar-
cerated women.  Int J Law Psychiatry.  1999 : 22(3-4) :301-22.
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7COLPOSCOPIC EXAMINATION 
(with endocervical assessment)
NO CIN/CANCER
ASC-US Pap ASC-H or LSIL Pap AGC 'favor neoplasia' AGC-NOS Pap        Manage
or AIS or HSIL Pap Per ASCCP
Guidelines**
(with expert
Repeat cytology* Review of Material Review of Material Repeat cytology*    guidance)
at 6 &12 months            (referral cytology, (referral cytology, at 4-6 month 
colpo^ findings & colpo^ findings & intervals X 4
all biopsies) all biopsies)
Follow ASCCP
guidelines**
If  either      Negative
Pap >ASC
No change Change in      No change Change in
diagnosis diagnosis
Repeat   Routine 
Colpo^ screening
annually  Follow ASCCP Follow ASCCP
or guidelines** guidelines**
in six mos X 1 
if a new Repeat cytology         Diagnostic excisional
HIV diagnosis ± colpo^ procedure
every six mos until
regression or 
progression of CIN^^
(with expert guidance)
CIN/CANCER
Little is known about the best management of abnormal cervical cytology among HIV-infected women. This flow chart is a suggested
algorithm created by an expert in the field and is based on the American Society for Colposcopy and Cervical pathology (ASCCP) guide-
lines (www.asccp.org/consensus.shtml) and the most current available research on this topic. All HIV-infected women with any Pap
abnormality should be referred for colposcopy. This algorithm assumes that the Pap report states "satisfactory for evaluation."  If the Pap
is "unsatisfactory for evaluation," it should be repeated. No HPV testing triage is recommended in HIV-infected women at this time, based
on insufficient evidence to support clinical or cost-effective utility.
=If unsatisfactory colposcopic examination, refer to expert 
^^May depend on status of immune function (i.e. CD4 cell count and HIV
viral load burden)
^Colpo = colposcopy
* Conventional or liquid-based
** Visit: www.asccp.org/consensus.shtml
Abbreviations Defined:
ASC-US = atypical squamous cells of undetermined significance (mild
atypia)
ASC-H = atypical squamous cells: cannot exclude high-grade squamous
intraepithelial lesion 
HSIL = high-grade squamous intraepithelial lesion 
AGC = atypical glandular cells 
AGC-NOS = atypical glandular cells, not otherwise specified (also known
as 'atypical glandular cells of undetermined significance')
CIN = cervical intraepithelial neoplasia
AIS = adenocarciinoma in situ
LSIL = Low-grade squamous intraepithelial lesions
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IDCR-O-GRAM: Suggested Management of HIV-Infected Women with ANY
Cytological Abnormality (ASC-US, ASC-H, AGC, LSIL, HSIL)
Centerforce Inside-Out
Summit
September 10-13, 2005
San Francisco, CA
Visit: www.centerforce.org/
summit
ICAAC Meeting
September 21-24, 2005
New Orleans, LA
Visit: www.icaac.org
United States Conference on
AIDS
September 28-October 2, 2005
Houston, TX
Visit: www.nmac.org
IDSA Conference
October 6-9, 2005
San Francisco, CA
Visit: www.idsociety.org
National Conference on
Correctional Health Care
October 8-12, 2005
Denver, CO
Visit: www.ncchc.org
Society of Correctional
Physicians Annual Meeting
October 9, 2005
Denver, CO
Visit: www.corrdocs.org
Management of HIV/AIDS in
the Correctional Setting: A
Live Satellite Videoconference
Series
"Drug-drug Interactions and
Metabolic Complications of HIV"
October 26, 2005
Visit: www.amc.edu/patient/
hiv/hivconf/index.htm
APHA Meeting and Exposition
November 5-9, 2005
New Orleans, LA
Visit: www.apha.org
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Errata: Vol. Vol. 8, Issue 4
In the IDCR, "Managing STIs in Jails," two errors
occurred.  On page two, column one, in section
three, the unpublished data from a study on male
inmates in the NYC jail system should read,
"Unpublished data from a recent study on male
inmates in the NYC jail system revealed a rela-
tively high rate of asymptomatic chlamydial infec-
tion, especially in males 35 years and younger."
The subsequent sentence should read, "This
finding led to the current universal screening for
chlamydia and gonorrhea in all males younger
than 35 years in the NYC jail system."
25% of Women in WIHS Stop HAART
A recent analysis of the Women's Interagency
HIV Study (WIHS) has demonstrated that 25% of
women stop highly active antiretroviral therapy
(HAART) for at least six months during study fol-
low-up of five years. The risk of discontinuation
was over one and a half times greater after 1998
as compared to the two and a half years preced-
ing 1998.  Discontinuers were more likely to be
African-American or Latina and less likely to be
white.  Additionally, discontinuers were more like-
ly to have had AIDS, lower median increase in
CD4 cell count, higher viral loads, and were more
likely to be depressed. Adieh-Grant, et al. sug-
gest that access to treatment for depression may
be helpful and that poor adherence is associated
with depressive symptoms.
Ahdieh-Grant, et al. JAIDS. 2005; 38(4):500-03.
CD4 Count Predicts Cervical SILs
Current cervical cancer screening guidelines
state that the interval between screenings can be
safely extended to three years in healthy HIV-
uninfected women 30 years and older who have
normal cytology results and negative test results
for HPV DNA.  Harris, et al. analyzed data from
the Women's Interagency HIV Study (WIHS), an
observational cohort study, to determine the inci-
dence of squamous intraepithelial lesions (SILs)
in HIV-infected women with normal cytology
results, by baseline oncogenic human papillo-
mavirus (HPV) DNA results. The incidence of
SILs were estimated according to baseline HPV
DNA, stratified by HIV serostatus and CD4 cell
count. Development of SILs in women with nega-
tive HPV results at two years was as follows: in
HIV-infected women with CD4 cell counts less
than 200/ul, 9%; with CD4 cell counts between
200ul and 500ul, 9%; and with CD4 cell counts
greater than 500/ul, 4%. At two years,
Multivariate Cox models showed that there was
not a significant difference in the incidence of any
SILs between HIV-infected and HIV-uninfected
women who had CD4 cell counts greater than
500/ul. Harris et al. concluded that the similar low
cumulative incidence of any SIL among HIV-
inf cted and HIV-uninfected women with CD4
counts greater than 500/ul and who had normal
cervical cytology and negative results for onco-
genic or all HPV DNA tests at baseline suggests
that similar cervical screening may be applicable
to both groups, although the authors note that
this strategy warrants further study in an appro-
priately designed trial.
Harris, et al. JAMA. 2005; 293(12):1471.
Breast/Uterine Cancer Reduced in Women
with AIDS
James Goedert, MD told participants at the 96th
annual meeting of the American Association for
Cancer Research that women with AIDS have a
l wer risk of developing cancer of the breast and
uterine corpus, perhaps because of alterations in
body fat and hormone imbalance. Of 77,739
women with AIDS who were followed from five
years, prior to, and 10 years after, AIDS diagno-
sis, 274, 31, and 29, developed breast cancer,
ovarian cancer, and cancer of the uterine corpus,
respectively. The incidence of breast cancer was
32% less in women with AIDS compared to
women without AIDS.  
96th annual meeting of the American Association
for Cancer Research. April 2005: Anaheim, CA.
www.natap.org
NCCHC Update: "Love Me Tender" Program
Approximately 3% of the total female population
incarcerated in the Texas Department of Criminal
Justice (TDCJ) are pregnant upon entry and 61%
are of child-bearing age.  Many of these women
r  pregnant for the first time and have little or no
prenatal care prior to incarceration. To address
these factors, TDCJ developed the "Love Me
Tender" program.  Pregnant women are housed
together and are transported to the labor and
delivery unit at the University of Texas Medical
Branch (UTMB) to have their babies. They are
subsequently housed in a unit in the TDCJ hospi-
tal and UTMB nursery staff cares for the babies
until discharge. Newborns are brought to see
their mothers Monday through Friday for two
hours to encourage bonding. Previously, incar-
cerated women who delivered their babies at
UTMB were only allowed a one-time visit with
their newborn during hospitalization. Outcomes
of this program have demonstrated improved
self-esteem, improved behavioral relationships,
and a commitment to avoid re-incarceration.
National Commission on Correctional
Healthcare: "Love Me Tender" Program session.
IN THE NEWS
RESOURCES
Women, Children, and HIV: Resources for Prevention and
Treatment
www.womenchildrenhiv.org
The Well Project
www.thewellproject.com
Maternal-Child HIV Transmission, Perinatal Guidelines
http://aidsinfo.nih.gov/guidelines/default_db2.asp?id=66
Animation: Mechanisms of Insulin Resistance in HIV-Infected
Patients 
http://clinicaloptions.com/hiv/manage/metabolics/#metabolics_glu-
cose
American Society for Colposcopy and Cervical Pathology
(ASCCP) Consensus Guidelines 
www.asccp.org/consensus.shtml
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SELF-ASSESSMENT TEST FOR CONTINUING MEDICAL EDUCATION CREDIT
Brown Medical School designates this educational activity for one hour in category one credit toward the AMA Physician’s Recognition
Award. To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through November 30, 2005. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1.  Which of the following is not true?
a. The prevalence of mental illness in incarcerated women is 
much higher than the prevalence of mental illness among 
women who are not incarcerated.
b. Male-to-female HIV transmission is more efficient than 
female-to-male HIV transmission.
c. High prevalence rates of gonorrhea, chlamydia, and 
syphilis exist among HIV-infected incarcerated women.
d. Persons who are co-infected with HIV and an STI may 
have decreased HIV shedding in genital secretions.
e. None of the above.
2.  HIV prevalence among women in U.S. federal and state 
prisons is approximately two times greater than HIV prevalence
among men in similar facilities.  True or False?
a. True
b. False
3.  The percentage of women who do not see their children at all
while incarcerated is closest to which of the following?
a. 25%
b. 50%
c. 75%
d. 100%
4.  HIV education and testing should be offered on multiple occa-
sions to women who:
a. Are pregnant
b. Have a history of drug use
c. Have a history of sex work
d. Have HBC or HCV
e. All of the above
5.  According to the ASCCP guidelines, all HIV-infected women
with any cytologic abnormality should be referred for colposcopy.
True or False?
a. True
b. False
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IDCR EVALUATION
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
In the News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that IDCR helps you in your work?
Why or why not?
3. What future topics should IDCR address?
4. How can IDCR be made more useful to you?
5. Do you have specific comments on this issue?
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